QR Code

CD34 and FSHR Expression to Differentiate Multiple Subtypes of Benign and Malignant Renal Neoplasms

BackgroundCurrently, no markers accurately differentiate benign from malignant renal masses. CD34 and FSHR are transmembrane proteins involved in neo-angiogenetic pathways and are differently expressed in several normal and cancerous tissues. However, little evidence exists on their distribution in...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Giancarlo Marra, Didier Meseure, Marine Lefèvre, Andre Nicolas, Laetitia Lesage, Nicolae Ghinea, Marco Moschini, Caio Pasquali, Petr Macek, Claudia Filippini, Paolo Gontero, Rafael Sanchez-Salas, Xavier Cathelineau
Hōputu: Artigo
Reo:Inglês
I whakaputaina: MDPI AG 2022-05-01
Rangatū:Société Internationale d’Urologie Journal
Ngā marau:
kidney cancer
cd34
fshr
tumor markers
Urunga tuihono:https://siuj.org/index.php/siuj/article/view/183/115
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite